SEC Comment Letter 0000000000-26-005261 to Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc.
Date: May 22, 2026 · CIK: 0001279704 · Accession: 0000000000-26-005261
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296036
Letter
May 22, 2026 James V. Caruso President and Chief Executive Officer Cellectar Biosciences, Inc. 100 Campus Drive Florham Park, New Jersey 07932 Re: Cellectar Biosciences, Inc. Registration Statement on Form S-1 Filed May 19, 2026 File No. 333-296036 Dear James V. Caruso: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nick D. DeAngelis, Esq.
Show Raw Text
May 22, 2026 James V. Caruso President and Chief Executive Officer Cellectar Biosciences, Inc. 100 Campus Drive Florham Park, New Jersey 07932 Re: Cellectar Biosciences, Inc. Registration Statement on Form S-1 Filed May 19, 2026 File No. 333-296036 Dear James V. Caruso: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nick D. DeAngelis, Esq.